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Background: Family psychoeducation is a relatively simple and straightforward intervention whose prophylactic
effectiveness and cost-effectiveness is well-established for schizophrenia. We have recently demonstrated its effectiveness
for unipolar depression, but its cost-effectiveness has never been examined. We hereby report a cost-effectiveness analysis
alongside a randomized controlled trial in order to assess its cost-effectiveness for preventing relapse/recurrence in
depression.
Methods: Fifty-seven patients diagnosed with major depression and undergoing its maintenance treatment, and their
primary family members were randomized to treatment as usual (TAU) only or to TAU plus family psychoeducation,
which consisted of four 2-hour multiple-family sessions consisting of didactic lectures about depression (30 minutes) and
group discussion and problem solving (60–90 minutes). The economic analyses were undertaken from the perspective of
the National Health Insurance (NHI), assuming the most reasonable price of US$50 per psychoeducation session per
patient. The main outcome measures included relapse-free days and direct costs to the NHI.
Results: The intervention group enjoyed 272 (SD: 7.1) relapse-free days, while the control group spent 214 (SD: 90.8)
relapse-free days (Cox proportional hazard ratio=0.17, 95%CI: 0.04 to 0.75, p= 0.002). Cost-effectiveness acceptability
curves suggested that the family psychoeducation has 90% or more chances of being cost-effective if the decision-maker
is prepared to pay US$20 for one additional relapse-free day. This cost-effectiveness finding was robust when the price for
family psychoeducation ranged between 50% to 150% of the baseline scenario in sensitivity analyses. If a relapse-free day
is considered to be worth $30 or more, all the pricing scenarios have a close to 100% probability of being cost-effective.
Conclusion: Family psychoeducation is effective in the relapse prevention of depression and is highly likely to be cost-
effective if a relapse-free day is valued as US$20 or more.
Trial registration: UMIN-CTR (UMIN000005555)Background
Depression is a prevalent [1], chronic [2] and relapsing
[3] disorder. Pharmacotherapy, while moderately effect-
ive in alleviating acute depression [4] and in preventing
relapse/recurrences [5], can nevertheless provide only
partially satisfactory solutions to the patients’ sufferings
[6]. It is evident that we need concerted efforts in both* Correspondence: furukawa@kuhp.kyoto-u.ac.jp
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distribution, and reproduction in any mediumsomatic and non-somatic approaches to lessen the dis-
ease burdens for these patients and their families. We
have recently demonstrated the efficacy of a new
approach to recurrent depression, namely family psy-
choeducation [7], which has been proven to be effective
and cost-effective for the treatment of schizophrenia
[8,9]. Whether family psychoeducation for depression is
cost-effective, however, has never been examined.
This study presents an economic evaluation that we con-
ducted alongside a randomized controlled trial to establish
the cost-effectiveness of additional family psychoeducation
versus no add-on treatment in the context of long-term
continuation/maintenance treatment for major depression.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Participants
The details of the study participants and procedures are
given elsewhere [7] and are briefly summarized below.
The patients were recruited at the Department of
Psychiatry, Kochi Medical School, or its affiliated hos-
pital, Doujin Hospital, between April 2004 and April
2006. The inclusion criteria for the patients were as
follows:
1. Aged 18–85 years.
2. Diagnosed as suffering from major depressive
disorder according to the DSM-IV[10]
3. Expected to be on continuation/maintenance
antidepressant therapy for at least nine months after
the patients had responded to acute phase
antidepressant therapy and were in partial or full
remission, i.e. they no longer fulfilled the diagnostic
threshold for major depressive episode
4. Not having undergone electroconvulsive therapy or
not having electroconvulsive therapy already
planned for the index episode
5. Living with the family for 3 months or longer before
participating in this study and being expected to live
with the family during the investigation period
6. Having at least one family member living with the
patient who was available for family interviews.
The following patients were excluded:
1. Patients were screened with the Mini-Mental Status
Examination [11] when dementia was clinically
suspected and those scoring 23 or below were
excluded.
2. Patients suspected of having organic diseases were
examined using head magnetic resonance imaging,
and those diagnosed as such were excluded.
The member of each family who was 18 years or
older and who had contact with the patient for the
longest time was regarded as his/her primary family
member.
Of the 103 patients who met the above eligibility cri-
teria, 57 patients and their family member provided
written informed consent to participate in this study
after full disclosure of the purposes and procedures of
the study. The major reason for non-consent was that
the primary family members were unable to participate
in the four psychoeducation sessions because of their
work.
This study was approved by the Ethics Committee of
Kochi Medical School, and written informed consent
was given by all the patients and their families. The trial
is registered with UMIN-CTR (UMIN000005555).Procedure
The fifty-seven patients who consented were randomly
allocated to the intervention and control groups and
were followed up for nine months. A random sequence
was generated using a random number table and was
kept by an independent clerk who allocated the consecu-
tive patient sample to the intervention or control groups.
No stratification was used.
Both the intervention and control groups received the
standard outpatient treatment, which was performed by
psychiatrists who were kept unaware of the treatment al-
location of the patients. This treatment as usual (TAU)
consisted of an evaluation of psychiatric symptoms,
assessment and management of drug treatment, and
supportive psychotherapy on a bi-weekly basis. All the
patients were kept on maintenance antidepressants.
The primary family members in the intervention group
took part in family psychoeducation sessions with mul-
tiple primary family members without the participation
of the patients. Only one family member per patient was
allowed. The session was performed once every 2 weeks,
and 4 sessions were regarded as one course. The themes
of the four sessions were “Epidemiology and causes,”
“Symptoms,” “Treatment and course,” and “Coping of
the family with the patient.”
Each session lasted 90–120 minutes. The first 30 minutes
were devoted to providing information regarding depres-
sion and its treatment. A video tape and a textbook
explaining depression and its treatment were prepared for
this study and were used as teaching materials. The next
60–90 minutes were devoted to group discussion and
problem solving for emotionally difficult situations experi-
enced by participating families.
In order to maximally facilitate group discussion, the
number of participating family members was limited to
five, while from the staff side, one leader and two co-
leaders, usually consisting of two psychiatrists and one
psychologist, attended each session. The whole program
was supervised by SI, who had 30 years of experience in
psychoeducation for people with severe mental illness.
The sessions were videotaped, and the treatment team
discussed their performance after the session was over.
Cost and clinical assessments
The economic analyses were undertaken from the
perspective of the direct costs to the National Health In-
surance (NHI). In Japan, all medical expenditures are
priced by the NHI, of which 70% are reimbursed by the
NHI and 30% are paid by the patients out of their own
pocket, except in special circumstances. We therefore
asked the patients to collect all their NHI bills and
summed them for the duration of the study. The sums
included both the 70% reimbursed and the 30% paid out
of the patients’ own pocket. Non-health service
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the analyses. The costs in Japanese yen were all con-
verted to US dollars at a rate of 100 yen/ 1 US dollar,
which is the rough average exchange rate for the past
several years at the time of writing of this manuscript
(November 2011).
To evaluate the depressive state, we administered the
Hamilton Rating Scale for Depression (HAM-D) [12] and
the Beck Depression Inventory (BDI) [13] before interven-
tion and after 9 months. The treating psychiatrist, who
was blinded to the intervention status, administered the
HAM-D. The BDI-II was filled in by the patient himself.
When the treating psychiatrist who was blinded to the
allocated intervention recognized the re-emergence of a
major depressive episode according to the DSM-IV in the
course of the bi-weekly visits constituting the treatment as
usual, the patient was referred to an independent psych-
iatrist who also was kept blind to the intervention group
and who administered the HAM-D and BDI. Relapse/
recurrence was declared when the diagnostic threshold
for a major depressive episode as specified in the DSM-
IV was met according to the interview by this inde-
pendent psychiatrist. The number of depression-free
days up to the relapse/recurrence was taken as the unit
of effectiveness.
Analyses
The time to relapse/recurrence was compared between
the two groups using a Cox proportional hazard analysis.
The arithmetic means of the relapse-free days and the
NHI costs were compared by way of the non-parametric
bootstrap method because the data had highly skewed
distributions [14].
Cost-effectiveness was evaluated by relating the differ-
ential cost per patient receiving either the intervention
or the control treatment to the differential effectiveness
of each treatment in terms of relapse-free days. The in-
cremental cost-effectiveness ratio (ICER) was calculated
as the difference in the mean cost divided by the differ-
ence in the number of relapse-free days.
A cost-effectiveness acceptability curve (CEAC) was
drawn to show the probability that an intervention is
cost-effective compared with the alternative, given the
observed data, for a range of maximum monetary values
that a decision-maker might be willing to pay for a par-
ticular unit change in outcome. The CEAC is derived
from the joint distribution of incremental costs and in-
cremental effects, as estimated by non-parametric boot-
strapping of the observed data [15]. The range of
maximum monetary values per relapse-free day is given
on the x-axis. Given a specified value of this ‘acceptable’
cost-effectiveness ratio (a point on the x-axis), the CEAC
shows the probability that the data are consistent with a
true cost-effectiveness ratio falling below that value (readoff the y-axis). This approach avoids the difficulties asso-
ciated with the estimation of confidence intervals for the
ICER.
In Japan, family psychoeducation is not yet covered by
the NHI and therefore is not yet priced. In this RCT
psychoeducation sessions were therefore administered as
a research intervention without any cost to the NHI or
the patients. In this cost-effectiveness analysis we
estimated the most reasonable cost of family psychoedu-
cation as follows and drew CEACs under this and two
more cost scenarios whereby the price was estimated at
50% and 150% of the baseline scenario. Given that three
therapists, whose average wage can range between US
$30 to $50 per hour including social security costs,
attended each 2-hour session for five patients, we calcu-
lated that the most reasonable estimate of one family
psychoeducation session would be US$50 per patient.
We also performed two sensitivity analyses in which a
session would be priced at US$25 and $75 per patient.
All data were analyzed using SPSS 18.0. The bootstrap
re-sampling was performed with STATA 11.0. Except
where otherwise noted, the means of continuous vari-
ables are reported, followed by the SD in parentheses.
Results
Clinical outcomes
Of the 57 patient-family member pairs who originally
consented and were randomized, 3 withdrew their con-
sent after randomization (one family member in the
intervention group and another in the control group
refused to undergo the baseline assessments and one
patient in the control group died from a physical illness),
resulting in 24 and 30 evaluable patients for the inter-
vention and control groups, respectively. The baseline
characteristics of the two groups showed that the groups
were closely comparable for all key variables (Table 1).
All 54 patients continued the treatment for 9 months
and were assessed at follow-up. One patient in each
group had stopped taking medication by the time of the
follow-up. A relapse occurred before completion of the
9-month follow-up in 2 patients (8%) in the intervention
group and in 15 patients (50%) in the control group
(Cox proportional hazard ratio = 0.17, 95%CI: 0.04 to
0.75, p = 0.002). The intervention group enjoyed 272
(SD: 7.1, Range: 242 to 274) relapse-free days while the
control group spent 214 (SD: 90.8, Range: 16 to 274)
relapse-free days by the time of the 9-month follow-up
(p = 0.009 using the bootstrap method).
Cost outcomes
The total NHI costs were US$1,842 (SD: 2,656, Range:
173 to 9,600) for the intervention group and US$2,638
(SD: 5,605, Range: 197 to 24,472) for the control group
(p = 0.509 using the bootstrap method). This increased
Table 1 Baseline characteristics of the patients and the
family members
Intervention
group (n = 24)
Control
group (n = 30)
Patients
Sex (Male:Female) 15:9 15:15
Age (Year) 59.2 (14.6) 60.9 (13.0)
Illness duration (Year) 11.6 (2.7) 11.0 (2.0)
Number of previous admissions 0.8 (1.2) 0.8 (1.9)
Antidepressant dosage
(imipramine equivalent)
100.3 (71.5) 88.1 (60.9)
HAM-D 13.4 (8.3) 13.7 (10.5)








Age(year) 59.0 (11.4) 61.8 (10.7)
Years of Education 12.0 (2.9) 10.7 (3.4)
HAM-D: Hamilton Rating Scale for Depression.
BDI: Beck Depression Inventory.
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days in the control group. Thus, the intervention was
significantly superior to the control in terms of effective-
ness and non-significantly so in terms of the total NHI
cost when family psychoeducation was not charged.
However, if psychoeducation is properly priced and
reimbursed, this cost difference may diminish or even be
reversed. We therefore assumed the most reasonable
price for a family psychoeducation session as well as two
more cost scenarios whereby a session was priced at
50% and at 150% of this most reasonable estimate.
Priced at US$50 session, the total NHI cost would rise
to US$2,042; if priced 50% lower, it would rise to US
$1942 and if priced 50% higher, it would rise to US
$2142.
Cost-effectiveness
We now examine the cost-effectiveness of the family
psychoeducation under these costing scenarios when the
additional benefits of increasing relapse-free days are
taken into consideration.
Figure 1 presents the CEACs for family psychoeduca-
tion plus TAU over TAU alone under the three scenarios
pricing attendance at a psychoeducation session at US
$25, US$50 or US$75. The curve indicates the probabil-
ity for the addition of family psychoeducation to be cost-
effective for a range of potential maximum amounts(ceiling ratio) that a decision-maker is willing to pay for
one more relapse-free day.
For example, even if the decision-maker does not value a
relapse-free day at all, the family psychoeducation priced at
US$50/session has an over 70% chance of being cost-
effective. If the decision-maker is prepared to pay US$10
for one additional relapse-free day, the family psychoeduca-
tion priced at US$50/session has a close to 90% chance of
being cost-effective. Sensitivity analyses indicate that even if
the price of family psychoeducation is 50% greater and is
priced at $75/session, it still has an over 80% chance of
being cost-effective; the probability rises to 90% if priced at
US$25/session.
If a relapse-free day is considered worth US$20, all the
pricing scenarios considered in this study have an over
90% probability of being cost-effective. If a relapse-free
day is considered worth US$30 or more, the probability
of being cost-effective is nearly 100%.
Discussion
We conducted a cost-effectiveness analysis of family psy-
choeducation in the context of a randomized controlled
trial to compare its addition to TAU against TAU alone in
the continuation/ maintenance treatment of major depres-
sion. Family psychoeducation significantly increased
relapse-free days in comparison with TAU. The cost-
effectiveness acceptability curves revealed that family psy-
choeducation is highly likely (>90%) to be cost-effective if
one values one relapse-free day at or above US$20 to $30
when one session of family psychoeducation is priced at
US$50 per patient. This cost-effectiveness finding was
robust even when the price for a session ranged between
50-150% of the baseline scenario.
There are many ways to estimate the utility score for
depression: one longitudinal study of patients receiving
depression treatment concluded that an incremental
quality-adjusted life year (QALY) from depressed to
non-depressed state was 0.24 to 0.25 [16], while one
cross-sectional study interviewing general population
samples as well as formerly and currently depressed
patients revealed that an incremental QALY between
non-depressed state and moderate to severe depression
ranged between 0.26 to 0.43 [17]. Because one QALY is
often valued at US$50,000 to $70,000 [18], the monetary
value of one depression-free day over one depressed day
would then range between US$30 to $80. Although our
relapse-free day may be valued somewhat less than a to-
tally depression-free day, these figures would still place
family psychoeducation at the rightmost end of the cost-
effectiveness acceptability curves depicted in our Figure 1
and beyond. It must also be remembered that all the
above arguments are based on direct heath care costs
only. Indirect morbidity and mortality costs far outweigh


































Value of ceiling ratio ($)
$25/session/patient $50/session/patient $75/session/patient
Figure 1 Cost-effectiveness acceptability curves showing the probability that the treatment program is cost-effective in comparison
with TAU (y-axis), as a function of a decision-maker’s ceiling cost-effectiveness value for one relapse-free day (x-axis), when the family
psychoeducation session is priced at US$ 25, $50 or $75.
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follows. First of all, the costing estimates were based on
the prices as set by the Japanese NHI, and we cannot be
sure how generalizable these estimates may be across
different health care systems. Secondly, we were able to
conduct sensitivity analyses around the psychoeducation
cost only and were unable to conduct sensitivity analyses
incorporating plausible ranges of drugs and other costs
because our cost assessments did not include these fig-
ures separately. Thirdly, we were also unable to adopt a
societal perspective to assess non-health care costs or in-
direct costs related to depression. Fourthly, the average
age of the patients in this trial was around 60 years. The
variability of our sample (2 in their 20s, 2 in their 30s, 6
in their 40s, 7 in their 50s, 9 in their 60s, 7 in their 70s,
and one in their 80s) may be biased towards older gen-
erations, and its applicability to younger generations
cannot be guaranteed, given the arguably different family
dynamics at different ages. However, it must be empha-
sized that the effectiveness of the family psychoeduca-
tion remained statistically significant when age of the
patient was entered into the Cox proportional hazard
analysis [7]. Fifthly, the follow-up in the current study
was only nine months. Whether the preventative effect
of our four-session family psychoeducation lasts after
this period is unknown. However, given the proportional
hazard observed in the time to relapse analyses, such a
possibility is more likely than not, and would further in-
crease the cost-effectiveness of the intervention. On the
other hand, even if the same relative decrease in relapse
persists after 9 months, such benefits may have to bediscounted, relative to more immediate gains as
observed in the current study. Lastly, the family psy-
choeducation program that we experimented with in this
trial may have particular strength in the Japanese con-
text, where family ties are stronger than in other indus-
trialized countries. The program may have to be slightly
modified when transferred to other cultural settings, for
example, by including the patients themselves if we want
to extend the current program to more individualistic
cultures.
Conclusion
Despite these possible limitations, we believe that our
economic analyses have provided compelling evidence
that family psychoeducation in the maintenance treat-
ment of depression is robustly cost-effective even when
one extra relapse-free day is valued as low as being
worth US$20 when family psychoeducation is priced at
US$50 per session per person. The findings were robust
when sensitivity analyses were conducted around this
price estimate. It is hoped that, once the program and
its (cost-)effectiveness are replicated in a few more trials
in Japan and other countries, family psychoeducation
may become an officially covered and widely provided
practice in mental health services for people with de-
pression and their families.
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